Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesDividends payablesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

cbdMD (YCBD) Cash & Equivalents (2016 - 2025)

cbdMD's Cash & Equivalents history spans 10 years, with the latest figure at $3.4 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 71.96% year-over-year to $3.4 million; the TTM value through Dec 2025 reached $3.4 million, up 71.96%, while the annual FY2025 figure was $2.3 million, 7.8% down from the prior year.
  • Cash & Equivalents for Q4 2025 was $3.4 million at cbdMD, up from $2.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $26.4 million in Q3 2021 and bottomed at $1.1 million in Q2 2025.
  • The 5-year median for Cash & Equivalents is $2.6 million (2023), against an average of $7.4 million.
  • The largest annual shift saw Cash & Equivalents skyrocketed 78.16% in 2021 before it plummeted 87.11% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $19.7 million in 2021, then crashed by 82.98% to $3.4 million in 2022, then crashed by 55.11% to $1.5 million in 2023, then surged by 30.92% to $2.0 million in 2024, then surged by 71.96% to $3.4 million in 2025.
  • Per Business Quant, the three most recent readings for YCBD's Cash & Equivalents are $3.4 million (Q4 2025), $2.3 million (Q3 2025), and $1.1 million (Q2 2025).